The new coronavirus mRNA vaccine candidate (ARCoV) developed by the Institute of Military Medical Sciences of the Chinese Academy of Military Sciences has been approved for clinical trials, which is the first mRNA vaccine approved for clinical trials in China.
Studies showed that the mRNA vaccine can not only induce high levels of neutralizing antibodies in mice and cynomolgus monkeys, but also induce a protective T-cell immune response.
Cynomolgus monkeys showed that the vaccinated animals could tolerate high titers of coronavirus attack and effectively prevent virus replication and lung pathology progression, showing good protective effect.
The mRNA vaccine is an emerging form of vaccine in recent years. Its basic principle is to introduce the mRNA expressing the antigen target into the body through a specific delivery system, to express the protein in the body and stimulate the body to produce a specific immunological response, so that the body can obtain immune protection.
At present, only a few mRNA vaccines developed by the United States and Germany have entered the clinical research stage. China has never approved an mRNA vaccine to enter clinical trials before.
Special Report: Fighting The New Coronavirus
